507
Participants
Start Date
November 16, 2022
Primary Completion Date
May 16, 2024
Study Completion Date
June 14, 2025
Bimagrumab
Human monoclonal antibody to the activin receptor type II
Semaglutide
Glucagon-like peptide-1 (GLP-1) receptor agonist
Placebo
Placebo
New Zealand Clinical Research Auckland, Auckland
Optimal Clinical Trials, Auckland
Middlemore Hospital, Auckland
Royal North Shore Hospital, Saint Leonards
Northern Beaches Clinical Research, Brookvale
Austin Health, Heidelberg Heights
Emeritus Research, Camberwell
Lakeland Clinical Trials Waikato, Hamilton
University of The Sunshine Coast South Brisbane, South Brisbane
Gold Coast University Hospital, Southport
University of The Sunshine Coast Morayfield, Morayfield
P3 Research, Newtown
Southern Clinical Trials Tasman, Nelson
New Zealand Clinical Research Christchurch, Christchurch
Southern Clinical Trials Ltd, Beckenham, Christchurch
Weill Cornell Medical College, New York
Monroe Biomedical Research, Monroe
SPICA Clinical, Columbia
Clinical Neuroscience Solutions Inc, Jacksonville
Indago Research & Health Center, Inc, Hialeah
Altus Research, Lake Worth
Cullman Clinical Trials, Cullman
Pinnacle Research Group, LLC, Anniston
Pennington Biomedical Research Center, Baton Rouge
Mt. Olympus Medical Research, Sugar Land
University of the Sunshine Coast Clinical Trial Centre, Sippy Downs
Versanis Bio, Inc.
INDUSTRY
Eli Lilly and Company
INDUSTRY